Loading…
Nidan Laboratories and Healthcare (NIDAN)₹13.35−0.37%Healthcare Service Provider
In the Mar 2026 quarter (standalone), Nidan Laboratories and Healthcare reported sales of ₹12.46 Cr, down 11.3% from Mar 2025, and net profit of ₹0.08 Cr, down 91.0% year on year. For the year to Mar 2026, sales were ₹25.63 Cr and net profit ₹1.52 Cr.
Company filings, standalone accounts; latest reported quarter Mar 2026
| Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Sales | 10.22 | 11.85 | 12.40 | 10.57 | 14.04 | 13.16 | 12.46 |
| Expenses | 8.53 | 8.47 | 9.23 | 7.92 | 11.52 | 10.56 | 10.11 |
| Operating Profit | 1.63 | 3.33 | 3.10 | 2.61 | 2.47 | 2.53 | 2.29 |
| OPM % | 16.1% | 28.3% | 25.2% | 24.6% | 17.5% | 19.3% | 18.5% |
| Other Income | 2.99 | 1.51 | −5.28 | 1.02 | 1.21 | 1.16 | 0.28 |
| Interest | 1.20 | 0.99 | 1.21 | 0.89 | 1.27 | 0.89 | 1.08 |
| Depreciation | 1.65 | 1.27 | 1.58 | 1.33 | 1.06 | 0.91 | 0.97 |
| Profit before tax | 1.78 | 2.59 | −4.96 | 1.40 | 1.34 | 1.90 | 0.53 |
| Tax % | 31.3% | 26.2% | 3.6% | 22.0% | 34.9% | 24.7% | 87.1% |
| Exceptional items | 0.00 | 0.00 | −5.98 | 0.00 | 0.00 | 0.00 | −0.04 |
| Net Profit | 1.23 | 1.93 | −5.16 | 1.11 | 0.89 | 1.44 | 0.08 |
| EPS (Rs) | 0.87 | 1.37 | −3.70 | 0.78 | 0.62 | 1.02 | 0.04 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales | 20.15 | 21.48 | 20.47 | 29.75 | 24.35 | 24.28 | 24.62 | 25.63 |
| Expenses | 12.21 | 13.76 | 11.47 | 20.23 | 17.45 | 17.73 | 19.45 | 20.67 |
| Operating Profit | 7.83 | 7.62 | 8.88 | 9.40 | 6.79 | 6.43 | 5.07 | 4.83 |
| OPM % | 39.0% | 35.6% | 43.6% | 31.7% | 28.0% | 26.6% | 20.6% | 18.9% |
| Other Income | 0.36 | 0.00 | 1.05 | 0.39 | 3.32 | −3.75 | 2.24 | 1.45 |
| Interest | 4.76 | 3.75 | 3.47 | 2.67 | 2.23 | 2.19 | 2.15 | 1.97 |
| Depreciation | 3.23 | 3.18 | 3.17 | 2.62 | 3.09 | 2.86 | 2.40 | 1.89 |
| Profit before tax | 0.21 | 0.70 | 3.30 | 4.51 | 4.80 | −2.36 | 2.75 | 2.43 |
| Tax % | 0.0% | 0.0% | 30.3% | 41.2% | 26.4% | 36.3% | 28.3% | 38.2% |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.21 | 0.21 | −3.22 | 0.01 | −0.24 |
| Net Profit | 0.23 | 0.72 | 2.31 | 2.67 | 3.55 | −3.24 | 1.99 | 1.52 |
| EPS (Rs) | 0.21 | 0.71 | 2.31 | 1.90 | 2.54 | −2.31 | 1.41 | 1.08 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 9.91 | 9.87 | 9.88 | 13.85 | 13.86 | 13.86 | 13.86 | 13.86 |
| Reserves | 0.41 | 1.14 | 3.44 | 52.04 | 55.59 | 52.30 | 54.31 | 55.79 |
| Borrowings | 32.23 | 34.38 | 38.06 | 19.28 | 10.94 | 12.43 | 11.10 | 11.17 |
| Other Liabilities | 0.59 | −0.17 | 2.38 | 3.31 | 4.03 | 3.88 | 3.67 | 3.16 |
| Total Liabilities | 43.14 | 45.22 | 53.76 | 88.48 | 84.42 | 82.47 | 82.94 | 83.98 |
| Fixed Assets | 23.39 | 20.17 | 20.00 | 20.53 | 21.49 | 18.01 | 16.38 | 14.97 |
| CWIP | 0.00 | 0.00 | 0.24 | 3.82 | 0.00 | 0.05 | 0.16 | 0.16 |
| Investments | 0.54 | 0.54 | 0.28 | 0.00 | 0.00 | 0.00 | 20.04 | 20.04 |
| Other Assets | 19.21 | 24.51 | 33.24 | 64.13 | 62.93 | 64.41 | 46.36 | 48.81 |
| Inventories | 0.09 | 0.10 | 0.12 | 0.21 | 0.36 | 0.31 | 0.54 | 0.54 |
| Trade receivables | 5.63 | 5.45 | 5.45 | 5.38 | 6.05 | 0.53 | 1.28 | 2.23 |
| Cash & equivalents | 4.33 | 7.37 | 7.28 | 8.08 | 8.39 | 2.84 | 1.89 | 1.98 |
| Total Assets | 43.14 | 45.22 | 53.76 | 88.48 | 84.42 | 82.47 | 82.94 | 83.98 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | 8.94 | 4.61 | 4.36 | 7.82 | 10.96 | 5.51 | 2.27 | 1.66 |
| Cash from investing activity | 1.01 | −0.02 | −3.23 | −35.76 | −0.30 | −10.61 | −0.23 | 0.07 |
| Cash from financing activity | −5.80 | −1.55 | −1.21 | 28.71 | −10.36 | −0.48 | −3.00 | −1.62 |
| Net cash flow | 4.13 | 3.04 | −0.09 | 0.79 | 0.31 | −5.56 | −0.94 | 0.09 |
| Capex | 0.00 | 0.02 | 3.23 | 7.08 | 0.68 | 0.75 | 0.95 | 0.49 |
| Free cash flow | 9.97 | 4.62 | 1.14 | 1.37 | 11.04 | 4.89 | 1.42 | 1.20 |
| CFO / OP % | 114.0% | 61.0% | 49.0% | 96.0% | 162.0% | 129.0% | 77.0% | 55.0% |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Debtor days | 101 | 92 | 96 | 65 | 90 | 7 | 18 | 31 |
| Inventory days | 17 | 13 | 18 | 26 | — | — | — | — |
| Days payable | 116 | −27 | 212 | 135 | — | — | — | — |
| Cash conversion cycle | 2 | 131 | −98 | −44 | 91 | 8 | 19 | 32 |
| Working capital days | 256 | 292 | −189 | 55 | 43 | 243 | −13 | 34 |
| ROCE % | — | 10.1% | 13.9% | 10.1% | 8.1% | 7.9% | 6.1% | 6.0% |
For the Mar 2026 quarter, Nidan Laboratories and Healthcare reported sales of ₹12.46 Cr, down 11.3% year on year and net profit of ₹0.08 Cr, down 91.0% year on year. The operating margin was 18.5%.
Nidan Laboratories and Healthcare's sales for the year to Mar 2026 were ₹25.63 Cr.
Net profit for the year to Mar 2026 was ₹1.52 Cr. Earnings per share over the same trailing period were ₹1.08.
Nidan Laboratories and Healthcare reported borrowings of ₹11.17 Cr at Mar 2026, against cash and equivalents of ₹1.98 Cr.
Cash from operations was ₹1.66 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹1.20 Cr.